TIME SENSITIVE: A Once in a Lifetime Event is Coming

Key Concepts

• AI Capex Cycle: A significant increase in capital expenditure driven by the demand for AI infrastructure (data centers, GPUs, power, cooling, networking).
• Financing Legs: The three sources of funding for AI infrastructure – cash financing (large tech companies), debt financing (bonds), and private equity financing.
• Sovereign Wealth Funds: Investment funds owned by national governments, increasingly investing in AI infrastructure.
• Lucid MS: Quantum Bioarma’s lead drug candidate for Multiple Sclerosis, aiming to repair damaged myelin rather than just suppress the immune system.
• Unbuzzed: Quantum Bioarma’s dietary supplement designed to accelerate alcohol metabolism, backed by clinical trial data.
• Net Retention Rate (NRR): A metric measuring customer retention and expansion, with >110% indicating strong growth.
• Net Debt to EBITDA: A leverage ratio used to assess a company’s debt burden relative to its earnings.

Market Setup for 2026 & AI Sell-Off

The speaker posits that 2026 presents a unique investment opportunity due to a confluence of factors: fiscal policy, monetary policy, deregulation, and the massive growth of AI. Despite recent AI stock sell-offs, driven by concerns about financing, the speaker argues this is a temporary wobble within a larger, long-term trend. The recent decline in AI trades, following a period of resurgence, is attributed to increasing skepticism and predictions of an “AI bubble” – a narrative fueled by media coverage highlighting potential risks. However, the speaker emphasizes the importance of understanding the underlying details and context, warning against making financial decisions solely based on fear.

The primary concern driving the sell-off is the financing of AI infrastructure buildout, which is incredibly expensive (data centers, GPU clusters, power, cooling). Hyperscaler capex is projected to reach $320 billion in 2025 and increase to $520-$530 billion in 2026. Initially, financing came from three sources: large tech companies’ cash flow, debt financing (bonds), and private equity. However, Oracle’s struggles with bond sales and a reported pullback from Blue Owl on a $10 billion data center project tied to OpenAI caused concern, leading to market panic.

Financing Rebound & OpenAI’s Funding

The speaker asserts that the financing situation is improving. The Federal Reserve’s potential shift towards rate cuts, combined with a renewed influx of capital, is bolstering the AI infrastructure buildout. Crucially, OpenAI is reportedly seeking to raise up to $100 billion in a private funding round, which would be the largest in history. This funding is coming from sovereign wealth funds (Saudi Arabia’s PIF, UAE, Norway’s pension fund), signaling a strong commitment to AI infrastructure from global capital. This influx of capital alleviates concerns about financing sustainability and reinforces the “AI arms race” between nations and hyperscalers. The speaker highlights that this level of funding signifies a valuation for OpenAI of approximately $830 billion.

Investment Sectors for 2026

The speaker identifies three key sectors poised for success in 2026:

1. AI Infrastructure: Focusing on “picks and shovels” plays rather than crowded trades like Nvidia. Specifically, the speaker emphasizes the critical need for power infrastructure (demand expected to increase 165% by 2030, potentially 30-fold for AI data centers) and transmission (bottlenecks in grid infrastructure create opportunities). Also highlighted are cooling solutions (35-40% of hyperscaler energy consumption) and networking (interconnects will be the limiting factor, not GPUs).
2. Financials: Undervalued and poised to benefit from a combination of factors: Fed rate cuts, yield curve normalization, deregulation, and a reopening of M&A and IPO pipelines.
3. Healthcare: A turnaround play, with healthcare stocks trading at multi-decade lows. Specific areas to watch include:
   • Biotech M&A: Many biotech companies trading below cash value, while pharma companies have substantial cash reserves.
   • GLP-1 Drugs: Explosive growth potential with 120+ drugs in development and a projected $100 billion market by 2030.
   • Healthcare IT: Focus on companies with recurring revenue.

Stock Selection Criteria

The speaker recommends focusing on stocks with the following characteristics:

• Sticky Software: Businesses with net retention rates (NRR) of 110% or higher and positive free cash flow.
• AI Second-Order Plays: Companies providing infrastructure for AI, not just hype-driven AI companies.
• Turnarounds: Companies with improving fundamentals and catalysts for growth.
• Strong Balance Sheets: Net debt to EBITDA ratio under 2.5x.
• Quality over Hype: Prioritizing quality companies over speculative, momentum-driven stocks.

Seven Steps to Prepare by December 31st

1. Clean Up Your Portfolio: Eliminate “hold and hope” positions – sell stocks you wouldn’t buy today.
2. Tax Loss Harvesting: Strategically sell losing positions to offset gains, but avoid selling stocks with long-term conviction.
3. Commit to Long-Term Investing: Avoid panic buying and selling; hold high-conviction stocks.
4. Know Where Strength Will Be in 2026: Focus on the sectors and characteristics outlined above.
5. Be Prepared for All Outcomes: Maintain a diversified portfolio and avoid excessive leverage.
6. Think Bigger Picture: Focus on long-term trends, not short-term fluctuations.
7. Understand AI Investment Horizon: Recognize that AI investments require a long-term perspective and won’t yield immediate profits.

Sponsored Segment: Quantum Bioarma (Q&M)

Quantum Bioarma is a biopharmaceutical company focused on neurodegenerative disorders, metabolic disorders, and alcohol misuse. They have two key assets:

• Lucid MS: A novel treatment for Multiple Sclerosis that aims to repair damaged myelin, unlike existing treatments that only suppress the immune system. Phase 1 trials showed safety and tolerability. They are preparing for Phase 2 efficacy trials.
• Unbuzzed: A dietary supplement that accelerates alcohol metabolism. A double-blind, placebo-controlled clinical trial demonstrated a 40% faster reduction in blood alcohol concentration and significant reductions in hangover symptoms. Quantum Bioarma licensed the consumer version to Unbuzzed Wellness, retaining equity and royalties.

The speaker emphasizes that Quantum Bioarma is not solely reliant on R&D spending, having completed clinical trials and secured strategic investments. However, he cautions that it is a small-cap biotech stock, inherently risky, and requires thorough due diligence.

Conclusion

The speaker concludes that 2026 presents a significant investment opportunity driven by a unique combination of economic and technological factors. By focusing on quality companies in key sectors, preparing financially, and maintaining a long-term perspective, investors can position themselves for success. The influx of capital, particularly from sovereign wealth funds, signals a strong commitment to AI infrastructure and alleviates concerns about financing sustainability. The speaker encourages viewers to conduct their own research and make informed investment decisions.